Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report

Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report

Bibliographic Details
Main Authors: Margaret Corrigan, Geoffrey Haydon, Fiona Thompson, Neil Rajoriya, Claire L Peplow, Stefan G Hubscher, Neil Steven, Gideon M Hirschfield, Matthew J Armstrong
Format: Article
Language:English
Published: Elsevier 2019-05-01
Series:JHEP Reports
Subjects:
Hepatitis
Immunotherapy
Infliximab
checkpoint
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555919300084
id doaj-a12bf07e09e54cd7a0828648464c5b08
record_format Article
spelling doaj-a12bf07e09e54cd7a0828648464c5b082020-11-25T03:08:08ZengElsevierJHEP Reports2589-55592019-05-01116669Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case reportMargaret Corrigan0Geoffrey Haydon1Fiona Thompson2Neil Rajoriya3Claire L Peplow4Stefan G Hubscher5Neil Steven6Gideon M Hirschfield7Matthew J Armstrong8National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK; Corresponding authors. Address: Liver Unit, 3rd floor Nuffield House, Queen Elizabeth University Hospital Birmingham, Birmingham, UK.The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UKThe Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UKThe Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UKThe Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UKDepartment of Cellular Pathology, University Hospitals Birmingham, Birmingham, UKInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UKNational Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, CanadaNational Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Corresponding authors. Address: Liver Unit, 3rd floor Nuffield House, Queen Elizabeth University Hospital Birmingham, Birmingham, UK.http://www.sciencedirect.com/science/article/pii/S2589555919300084HepatitisImmunotherapyInfliximabcheckpoint
collection DOAJ
language English
format Article
sources DOAJ
author Margaret Corrigan
Geoffrey Haydon
Fiona Thompson
Neil Rajoriya
Claire L Peplow
Stefan G Hubscher
Neil Steven
Gideon M Hirschfield
Matthew J Armstrong
spellingShingle Margaret Corrigan
Geoffrey Haydon
Fiona Thompson
Neil Rajoriya
Claire L Peplow
Stefan G Hubscher
Neil Steven
Gideon M Hirschfield
Matthew J Armstrong
Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
JHEP Reports
Hepatitis
Immunotherapy
Infliximab
checkpoint
author_facet Margaret Corrigan
Geoffrey Haydon
Fiona Thompson
Neil Rajoriya
Claire L Peplow
Stefan G Hubscher
Neil Steven
Gideon M Hirschfield
Matthew J Armstrong
author_sort Margaret Corrigan
title Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
title_short Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
title_full Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
title_fullStr Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
title_full_unstemmed Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
title_sort infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: a case report
publisher Elsevier
series JHEP Reports
issn 2589-5559
publishDate 2019-05-01
topic Hepatitis
Immunotherapy
Infliximab
checkpoint
url http://www.sciencedirect.com/science/article/pii/S2589555919300084
work_keys_str_mv AT margaretcorrigan infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
AT geoffreyhaydon infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
AT fionathompson infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
AT neilrajoriya infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
AT clairelpeplow infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
AT stefanghubscher infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
AT neilsteven infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
AT gideonmhirschfield infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
AT matthewjarmstrong infliximabforthetreatmentofrefractoryimmunerelatedhepatitissecondarytocheckpointinhibitorsacasereport
_version_ 1724667384513429504

Similar Items